Mirion to Detail Financial Targets and Long-term Strategy at Today’s Investor Day
Mirion Technologies (NYSE: MIR) is hosting an Investor Day at the New York Stock Exchange to present its updated strategic and financial outlook. The company projects revenue of $1.1 billion by 2028, with 6-8% organic revenue growth, and targets an adjusted EBITDA margin of 30%. For 2025, Mirion forecasts organic revenue growth of 5.5-7.5% and adjusted EBITDA of $215-230 million. The company highlights its position in nuclear power and cancer care markets, announcing an anti-dilutive share repurchase program and updated capital allocation strategy. Management will discuss market opportunities in nuclear power growth, cancer care dynamics, and operational excellence initiatives.
Mirion Technologies (NYSE: MIR) sta ospitando un Investor Day presso la Borsa di New York per presentare le sue prospettive strategiche e finanziarie aggiornate. L'azienda prevede ricavi di 1,1 miliardi di dollari entro il 2028, con una crescita organica dei ricavi del 6-8%, e punta a un margine EBITDA rettificato del 30%. Per il 2025, Mirion prevede una crescita organica dei ricavi del 5,5-7,5% e un EBITDA rettificato di 215-230 milioni di dollari. L'azienda evidenzia la sua posizione nei mercati dell'energia nucleare e della cura del cancro, annunciando un programma di riacquisto di azioni anti-diluitivi e una strategia di allocazione del capitale aggiornata. La direzione discuterà le opportunità di mercato nella crescita dell'energia nucleare, le dinamiche della cura del cancro e le iniziative di eccellenza operativa.
Mirion Technologies (NYSE: MIR) está organizando un Día del Inversor en la Bolsa de Nueva York para presentar su perspectiva estratégica y financiera actualizada. La empresa proyecta ingresos de 1.1 mil millones de dólares para 2028, con un crecimiento orgánico de ingresos del 6-8% y busca un margen de EBITDA ajustado del 30%. Para 2025, Mirion prevé un crecimiento orgánico de ingresos del 5.5-7.5% y un EBITDA ajustado de 215-230 millones de dólares. La compañía destaca su posición en los mercados de energía nuclear y atención del cáncer, anunciando un programa de recompra de acciones anti-dilutivo y una estrategia de asignación de capital actualizada. La gestión discutirá las oportunidades de mercado en el crecimiento de la energía nuclear, la dinámica de la atención del cáncer y las iniciativas de excelencia operativa.
Mirion Technologies (NYSE: MIR)는 뉴욕 증권 거래소에서 업데이트된 전략 및 재무 전망을 발표하는 투자자 데이(Investor Day)를 개최하고 있습니다. 회사는 2028년까지 11억 달러의 수익을 예상하고 있으며, 유기적 수익 성장률은 6-8%이며, 조정 EBITDA 마진 목표는 30%입니다. 2025년에는 Mirion이 유기적 수익 성장률을 5.5-7.5%로 예상하고, 조정 EBITDA는 2억 1500만 ~ 2억 3000만 달러로 예상합니다. 회사는 원자력 및 암 치료 시장에서의 입지를 강조하며, 희석 방지 주식 매입 프로그램과 업데이트된 자본 할당 전략을 발표했습니다. 경영진은 원자력 성장에 대한 시장 기회, 암 치료 동향, 그리고 운영 우수성 이니셔티브에 대해 논의할 것입니다.
Mirion Technologies (NYSE: MIR) organise une Journée Investisseur à la Bourse de New York pour présenter son horizon stratégique et financier mis à jour. L'entreprise prévoit un chiffre d'affaires de 1,1 milliard de dollars d'ici 2028, avec une croissance organique des revenus de 6 à 8%, et vise une marge EBITDA ajustée de 30%. Pour 2025, Mirion anticipe une croissance organique des revenus de 5,5 à 7,5% et un EBITDA ajusté de 215 à 230 millions de dollars. L'entreprise souligne sa position sur les marchés de l'énergie nucléaire et des soins contre le cancer, annonçant un programme de rachat d'actions anti-dilutif et une stratégie d'allocation de capital mise à jour. La direction discutera des opportunités de marché dans la croissance de l'énergie nucléaire, des dynamiques des soins contre le cancer et des initiatives d'excellence opérationnelle.
Mirion Technologies (NYSE: MIR) veranstaltet einen Investorentag an der New Yorker Börse, um seinen aktualisierten strategischen und finanziellen Ausblick zu präsentieren. Das Unternehmen prognostiziert Einnahmen von 1,1 Milliarden US-Dollar bis 2028, mit einem organischen Umsatzwachstum von 6-8%, und strebt eine adjustierte EBITDA-Marge von 30% an. Für 2025 erwartet Mirion ein organisches Umsatzwachstum von 5,5-7,5% und ein adjustiertes EBITDA von 215-230 Millionen US-Dollar. Das Unternehmen hebt seine Position auf den Märkten für Kernenergie und Krebsversorgung hervor und kündigt ein aktienverdünnendes Rückkaufprogramm sowie eine aktualisierte Kapitalzuweisungsstrategie an. Das Management wird die Marktchancen im Bereich des Wachstums der Kernenergie, die Dynamik der Krebsversorgung und Initiativen zur operationalen Exzellenz erörtern.
- Projected revenue growth to $1.1 billion by 2028
- Strong organic revenue growth target of 6-8% through 2028
- Adjusted EBITDA margin expansion target to 30% by 2028
- Adjusted Free Cash Flow Conversion target of 60% by 2028
- Implementation of share repurchase program to address dilution
- Foreign exchange rate headwind of 150 basis points expected for 2025
- 30 basis point revenue headwind from lasers business divestiture in 2024
- Lower interim Free Cash Flow Conversion of 39-48% for 2025
Insights
The financial outlook reveals significant growth potential with ambitious targets through 2028. The projected
The 2025 guidance demonstrates near-term momentum with organic revenue growth of
The announced share repurchase program signals management's confidence in the company's valuation and commitment to shareholder returns. The strategic positioning in nuclear power and cancer care markets provides defensive growth characteristics with strong secular tailwinds.
Mirion's strategic focus on nuclear power and cancer care positions it exceptionally well within two high-growth sectors. The nuclear power industry is experiencing a renaissance with new builds and small modular reactor developments, while cancer care continues to see increased demand for advanced treatment solutions.
The company's dual market strategy provides natural diversification and exposure to both infrastructure and healthcare spending. The emphasis on digital innovation and operational excellence suggests a transformation from a pure hardware provider to a more integrated solutions company, which typically commands higher margins and more stable revenue streams.
Leadership team to outline unique position within growing nuclear and cancer care markets
The event will feature presentations by members of Mirion’s leadership team, followed by a live question-and-answer session.
The Mirion management team will discuss the company’s updated strategic and financial outlook, including:
- Promising market tailwinds supporting nuclear power growth opportunities amidst new builds, the installed base and small modular reactor development;
- An update on cancer care market dynamics in both radiation therapy and nuclear medicine;
- A discussion of the company’s commitment to commercial and operational excellence;
- Advancements in digital and innovation strategies taking shape across the enterprise;
- Initial 2025 guidance and a long-term financial outlook for 2028;
- The announcement of an anti-dilutive and opportunistic share repurchase program; and
- An update to the company’s capital allocation strategy.
“This is a very exciting time in Mirion’s history, and I am thrilled to share our updated strategy and outlook with the investment community,” stated Mirion’s CEO, Thomas Logan. “We are uniquely positioned in the middle of two super trends taking place in nuclear power and cancer care, which I expect to deliver robust growth for the business in the years to come. With our focus on commercial and operational excellence, I am confident in our approach to expand and protect shareholder value in the short- and longer-term.”
Financial Projections
2028 Long-Term Financial Outlook
At the Investor Day, Mirion will provide its 2028 long-term financial outlook, including projected:
-
Revenue of approximately
$1.1 billion 6% -8% organic revenue growth -
Adjusted EBITDA margin of approximately
30% by 2028 -
Adjusted Free Cash Flow Conversion of approximately
60% of adjusted EBITDA by 2028; interim target of approximately50% of adjusted EBITDA by 2026
Organic revenue growth guidance excludes the impact of foreign exchange rates as well as any mergers, acquisitions and divestitures. Other modeling and guidance assumptions will be included in the appendix of the Investor Day presentation.
Initial 2025 Financial Guidance
In addition, Mirion will provide initial 2025 financial guidance, including:
-
Organic revenue growth of approximately
5.5% -7.5% ; includes an approximately 30 basis point lasers business divestiture headwind from 2024 -
Revenue growth of approximately
4.0% -6.0% ; includes a foreign exchange rate headwind of approximately 150 basis points -
Adjusted EBITDA and adjusted EBITDA margin of approximately
$215 million $230 million 24.5% -25.5% , respectively; includes a foreign exchange rate headwind to adjusted EBITDA of approximately$3.5 million -
Adjusted Free Cash Flow of approximately
$85 million $110 million 39% -48% of Adjusted EBITDA -
Assumes a
1.05 Euro -to-USD foreign exchange rate
The company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic and inorganic revenue, adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.
Strategic Partnership
Memorandum of Understanding Signed with Electronics Corporation of India Ltd
Mirion signed, with its Indian partner AdvanceTech, a Memorandum of Understanding with Electronics Corporation of India Ltd (ECIL), the leading player in this market, to support the rapid growth of
Share Repurchase Program
Will announce a
The company will also announce a share repurchase program for up to
The Board also authorized the company to enter into written trading plans under Rule 10b5-1 of the Exchange Act. Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading blackout periods or pursuant to insider trading laws. Under any Rule 10b5-1 trading plan, the company’s third-party broker, subject to United States Securities and Exchange Commission regulations regarding certain price, market, volume and timing constraints, would have authority to purchase the company’s Class A common stock in accordance with the terms of the plan. The company may from time to time enter into Rule 10b5-1 trading plans to facilitate the repurchase of its Class A common stock pursuant to its share repurchase program.
The company cannot predict when or if, or at what prices, it will repurchase any shares of Class A common stock as such stock repurchase program will depend on a number of factors, including constraints specified in any Rule 10b5-1 trading plans, price, general business and market conditions, the terms of the company's debt agreements and alternative investment opportunities. Further, the stock repurchase program may be suspended or terminated at any time by the company without prior notice. Information regarding share repurchases will be available in the company’s periodic reports on Form 10-Q and 10-K filed with the Securities and Exchange Commission as required by the applicable rules of the Exchange Act.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Exchange Act , as amended. Words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “strive”, “seeks”, “plans”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, our strategic partnership with EDF, the closure of our lasers business, macroeconomic trends, trends in cancer care, nuclear power and small modular reactor, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, and our future share capitalization. These forward-looking statements, including any financial guidance, do not reflect, and make no positive or negative assumptions regarding, any policies, laws or regulations that may be introduced, promulgated or implemented by the newly elected
You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Use of Non-GAAP Financial Information
In addition to our results determined in accordance with GAAP, we believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding our previously reported non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to full reconciliations, non-GAAP definitions and forward-looking statements available in the 3Q 2024 earnings presentation (link) and the 2024 Investor Day presentation to be posted on ir.mirion.com.
Channels for Disclosure of Information
Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com, SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion’s investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion’s website.
About Mirion
Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203090054/en/
For investor inquiries:
Eric Linn
ir@mirion.com
For media inquiries:
Erin Schesny
media@mirion.com
Source: Mirion
FAQ
What is Mirion's (MIR) revenue target for 2028?
What is Mirion's (MIR) projected EBITDA margin for 2028?
What are Mirion's (MIR) 2025 revenue growth projections?
What is Mirion's (MIR) expected Free Cash Flow for 2025?
